

ICD-10-PCS FY 2021 Update

NOTICE: On July 30, 2020, the Centers for Medicare and Medicaid Services (CMS) posted an addendum to the FY 2021 International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) that is effective August 1, 2020. Due to the unusual timing, these updates did not make it into the 2021 Edition of Optum360's ICD-10-PCS: The Complete Official Code Set print codebook. The specific changes have been outlined below.

New ICD-10-PCS Codes

XW013F5	Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
XW033E5	Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033F5	Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033G5	Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033H5	Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW043E5	Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043F5	Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
XW043G5	Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043H5	Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW0DXF5	Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
XW13325	Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW14325	Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5

ICD-10-PCS Index Changes

<p>A</p> <p>ACTEMRA® use Tocilizumab</p> <p>C</p> <p>Convalescent Plasma (Nonautologous) see New Technology, Anatomical Regions XW1</p> <p>G</p> <p>GS-5734 use Remdesivir Anti-infective</p> <p>K</p> <p>KEVZARA® use Sarilumab</p>	<p>N</p> <p>New Technology</p> <p>Plasma, Convalescent (Nonautologous) XW1</p> <p>Remdesivir Anti-infective XW0</p> <p>Sarilumab XW0</p> <p>Tocilizumab XW0</p> <p>O</p> <p>Other New Technology Therapeutic Substance</p> <p>XW0</p> <p>P</p> <p>Plasma, Convalescent (Nonautologous) XW1</p>	<p>R</p> <p>Remdesivir Anti-infective XW0</p> <p>S</p> <p>Sarilumab XW0</p> <p>T</p> <p>Tocilizumab XW0</p> <p>V</p> <p>Veklury use Remdesivir Anti-infective</p>
--	--	---

ICD-10-PCS Substance Key and Substance Definitions Table Changes

Substance Key

Trade Name or Synonym	ICD-10-PCS Value	PCS Section
ACTEMRA®	Tocilizumab (H)	New Technology (X)
GS-5734	Remdesivir Anti-infective (E)	New Technology (X)
KEVZARA®	Sarilumab (G)	New Technology (X)
Veklury	Remdesivir Anti-infective (E)	New Technology (X)

LPCS121

Substance Definitions

ICD-10-PCS Value	Trade Name or Synonym	PCS Section
Remdesivir Anti-infective (E)	Includes: GS-5734 Veklury	New Technology (X)
Sarilumab (G)	Includes: KEVZARA®	New Technology (X)
Tocilizumab (H)	Includes: ACTEMRA®	New Technology (X)

ICD-10-PCS Tabular Changes

NOTICE: Table XW0 has been updated to reflect the addition of new codes added to the ICD-10-PCS classification, effective August 1, 2020. These have been demarcated in the table with green font AND italics.

- X New Technology**
- W Anatomical Regions**
- Ø Introduction** Definition: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Explanation: None

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
1 Subcutaneous Tissue	3 Percutaneous	<i>F Other New Technology Therapeutic Substance</i> W Caplacizumab	5 New Technology Group 5
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>Ø</i> Brexanolone	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	2 Ceftazidime-Avibactam Anti-infective	1 New Technology Group 1
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>2</i> Nerinitide	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	3 Idarucizumab, Dabigatran Reversal Agent	1 New Technology Group 1
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>3</i> Durvalumab Antineoplastic	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	4 Isavuconazole Anti-infective 5 Blinatumomab Antineoplastic Immunotherapy	1 New Technology Group 1
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>6</i> Lefamulin Anti-infective	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated 9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>9</i> Ceftolozane/Tazobactam Anti-infective	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>A</i> Cefiderocol Anti-infective	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>B</i> Omadacycline Anti-infective	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy	3 New Technology Group 3
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>C</i> Eculizumab <i>D</i> Atezolizumab Antineoplastic	<i>6 New Technology Group 6</i>
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>E</i> Remdesivir Anti-infective	<i>5 New Technology Group 5</i>
3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>F</i> Other New Technology Therapeutic Substance	<i>5 New Technology Group 5</i>
3 Peripheral Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	<i>G</i> Sarilumab	<i>5 New Technology Group 5</i>
3 Peripheral Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4

DRG Non-OR XW033C3

XW0 Continued on next page

X New Technology
W Anatomical Regions
Ø Introduction

Definition: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
 Explanation: None

XWØ Continued

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
3 Peripheral Vein	3 Percutaneous	H Tocilizumab K Fosfomycin Anti-infective N Meropenem-vaborbactam Anti-infective Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	Ø Brexanolone	6 New Technology Group 6
4 Central Vein	3 Percutaneous	2 Ceftazidime-Avibactam Anti-infective	1 New Technology Group 1
4 Central Vein	3 Percutaneous	2 Neritide	6 New Technology Group 6
4 Central Vein	3 Percutaneous	3 Idarucizumab, Dabigatran Reversal Agent	1 New Technology Group 1
4 Central Vein	3 Percutaneous	3 Durvalumab Antineoplastic	6 New Technology Group 6
4 Central Vein	3 Percutaneous	4 Isavuconazole Anti-infective 5 Blinatumomab Antineoplastic Immunotherapy	1 New Technology Group 1
4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated 9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy	3 New Technology Group 3
4 Central Vein	3 Percutaneous	C Eculizumab D Atezolizumab Antineoplastic	6 New Technology Group 6
4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
4 Central Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
4 Central Vein	3 Percutaneous	H Tocilizumab K Fosfomycin Anti-infective N Meropenem-vaborbactam Anti-infective Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
9 Nose	7 Via Natural or Artificial Opening	M Esketamine Hydrochloride	5 New Technology Group 5
D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6

DRG Non-OR XWØ43C3

XWØ Continued on next page

X New Technology
W Anatomical Regions
Ø Introduction Definition: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
 Explanation: None

XWØ Continued

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance J Apalutamide Antineoplastic L Erdafitinib Antineoplastic R Venetoclax Antineoplastic T Ruxolitinib V Gilteritinib Antineoplastic	5 New Technology Group 5
G Upper GI H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocogene exuparvovec	6 New Technology Group 6

NOTICE: Table XW1 has been added to the ICD-10-PCS classification, effective August 1, 2020.

X New Technology
W Anatomical Regions
1 Transfusion Definition: Putting in blood or blood products
 Explanation: None

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
3 Peripheral Vein 4 Central Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5